July 24, 2009

LICENSEE: Babcock and Wilcox

FACILITY: Potential Application for a Medical Isotope Production System

SUBJECT: SUMMARY OF JULY 8, 2009, CATEGORY 1 PUBLIC MEETING BETWEEN THE BABCOCK AND WILCOX TECHNICAL SERVICES GROUP AND THE U.S. NUCLEAR REGULATORY COMMISSION TO DISCUSS THE POTENTIAL APPLICATION OF A MEDICAL ISOTOPE PRODUCTION SYSTEM

On July 8, 2009, a public meeting was held between the U.S. Nuclear Regulatory Commission (NRC) staff and representatives of the Babcock and Wilcox (B&W) Technical Services Group at NRC Headquarters, One White Flint North, 11155 Rockville Pike, Rockville, MD. The purpose of the meeting was to discuss B&W's potential application for a medical isotope production system (MIPS) to produce Molybdenum-99 (Mo-99).

By letters dated December 13, 2007, and February 12, 2009, B&W notified the NRC of its intent to submit a license application for its proposed MIPS. B&W plans to provide Mo-99 for use in the domestic medical industry.

A meeting summary is provided in Enclosure 1, and a list of attendees is provided in Enclosure 2. A copy of the presentation slides used at the B&W meeting is available in Agencywide Documents Access and Management System Accession Number: ML091900270.

Please direct any inquires to me at 434-326-1086 or electronic mail at Geoffrey.wertz@nrc.gov.

/RA by Kathryn M. Brock/

Geoffrey Wertz, Project Manager
Research and Test Reactors, Branch A
Division of Policy and Rulemaking
Office of Nuclear Reactor Regulation

Enclosures:
1. Meeting Summary
2. List of Attendees

cc: see next page

Babcock & Wilcox Medical Isotope Production System

W. E. Reynolds, MIPS Program Manager
Babcock & Wilcox Technical Services
2016 Mt Athos Rd
Lynchburg, VA 24504

Steve Schilthelm, MIPS Licensing Lead
Babcock & Wilcox Technical Services
2016 Mt Athos Rd
Lynchburg, VA 24504

Ellen Kuo
Government Relations Specialist
The Babcock & Wilcox Company
511 2nd St., NE
Washington, DC 20002

Prof. Alan J. Kuperman
LBJ School of Public Affairs
University of Texas
Drawer Y
Austin, TX 78713-8925

Lynne Fairobent
Manager of Legislative and Regulatory Affairs
AAPM
One Physics Ellipse
College Park, MD 20740

Noah G. Pope
MS-E521
Los Alamos National Laboratory
Los Alamos, NM 87545

Fu-Min Su, Ph.D.
Radiation Safety Officer & Radiochemistry Manager
Advanced Medical Isotope Corporation
6208 W. Okanogan Ave.
Kennewick, WA 99336

Jennifer Lacey
Office of Global Threat Reduction (NA-21)
National Nuclear Security Administration
1000 Independence Avenue SW
Washington DC 20585-1615

Crystal B. Dale
MS K575
PO Box 1663
Los Alamos, NM 87545

Jack Wentz
Lantheus Medical Imaging
331 Treble Cove Road
N. Billerica, MA 01862

Robert W. Atcher, Ph.D, MBA
University of New Mexico
Bioscience Div.
MS M888
Los Alamos National Laboratory
Los Alamos, NM 87545

Jim Lieberman
11804 Rosalinda Dr
Potomac, MD 20854

Kim E. Hammer
419 E. Potomac St.
Brunswick, MD 21716

William D. Erwin, M.S.
Senior Medical Physicist
Department of Imaging Physics – Unit 1352
The University of Texas M. D. Anderson Cancer Center
P.O. Box 301439
Houston, TX 77230-1439

Felix M. Killar, Jr.
Senior Director
Nuclear Energy Institute
1776 I St. NW Suite 400
Washington, DC 20006

Danielle Dean
1311 Duke Street
Alexandria, VA 22314

Daniel McDonald
104 Claybrook drive
Silver Spring, MD 20902

Michael Peters
Assistant Director, Regulatory and
Legislative Portfolio
Government Relations
American College of Radiology (ACR)
505 9th St. NW, Suite 910
Washington, DC 20004

Michael Welling
Director Radioactive Materials Program
Virginia Dept of Health
109 Governor St, Room 730
Richmond, VA 23219

James E. Kuo
Research Associate
Healthcare & Biotechnology
Dundee Securities Corporation
1 Adelaide Street East, Suite 2700
Toronto, ON M5C 2V9

Test, Research, and Training
Reactor Newsletter
University of Florida
202 Nuclear Sciences Center
Gainesville, FL 32611

Seth Damergy, CPA
Medical Devices Associate Analyst
Deutsche Bank
60 Wall Street, 16th Floor
New York, NY 10005

David W. Martin
Nuclear Sector Specific Agency
Office of Infrastructure Protection
Department of Homeland Security
4601 N. Fairfax Dr., Suite 110
Arlington, VA 22203

Richard J. Martin, J.D.
Senior Legislative and Regulatory Analyst
Government Relations
American Society for Radiation Oncology
8280 Willow Oaks Corporate Drive,
Suite 500
Fairfax, VA 22031

July 24, 2009

LICENSEE: Babcock and Wilcox

FACILITY: Potential Application for a Medical Isotope Production System

SUBJECT: SUMMARY OF JULY 8, 2009, CATEGORY 1 PUBLIC MEETING BETWEEN THE BABCOCK AND WILCOX TECHNICAL SERVICES GROUP AND THE U.S. NUCLEAR REGULATORY COMMISSION TO DISCUSS THE POTENTIAL APPLICATION OF A MEDICAL ISOTOPE PRODUCTION SYSTEM

On July 8, 2009, a public meeting was held between the U.S. Nuclear Regulatory Commission (NRC) staff and representatives of the Babcock and Wilcox (B&W) Technical Services Group at NRC Headquarters, One White Flint North, 11155 Rockville Pike, Rockville, MD. The purpose of the meeting was to discuss B&W's potential application for a medical isotope production system (MIPS) to produce Molybdenum-99 (Mo-99).

By letters dated December 13, 2007, and February 12, 2009, B&W notified the NRC of its intent to submit a license application for its proposed MIPS. B&W plans to provide Mo-99 for use in the domestic medical industry.

A meeting summary is provided in Enclosure 1, and a list of attendees is provided in Enclosure 2. A copy of the presentation slides used at the B&W meeting is available in Agencywide Documents Access and Management System Accession Number: ML091900270.

Please direct any inquires to me at 434-326-1086 or electronic mail at Geoffrey.wertz@nrc.gov.

/RA by Kathryn M. Brock/
Geoffrey Wertz, Project Manager
Research and Test Reactors, Branch A
Division of Policy and Rulemaking
Office of Nuclear Reactor Regulation

Enclosures:
1. Meeting Summary
2. List of Attendees

cc: see next page

DISTRIBUTION:

PUBLIC	GLappert, NRR	AAdams, NRR
RidsOgcMailCenter	RidsNrrAdro	KBrock, NRR
RTR r/f	GWertz,	MAdams, NMSS
RidsOpaMail	NRRRidsOpaMailCenter	DHowe, FSME
RidsNrrDprPrta	TReed, NRR	WSchuster, NRR
RidsNrrOpa	SUttal, OGC	
RidsNrrDprPrtb	MRoss-Lee, NRR	

Package No.: ML091900346 **MTG Notice: ML091660665** **B&W Slides: ML091900270**
ADAMS ACCESSION NO.: ML091900741 ***concurrence by e-mail** **TemplateNo.: NRC-001**

OFFICE	PRTA:PM	PRTA:LA	PRTA:BC
NAME	GWertz GAW*	GLappert	KBrock
DATE	7/24/2009	7/22/2009	7/23/2009

OFFICIAL RECORD COPY

JULY 8, 2009 MEETING SUMMARY

RE: BABCOCK AND WILCOX POTENTIAL APPLICATION

FOR MEDICAL ISOTOPE PRODUCTION SYSTEM

In the meeting introduction, The US Nuclear Regulatory Commission (NRC) management notified Babcock and Wilcox (B&W) that Mary Jane Ross-Lee had been designated as the NRC point of contact for the project and any future communications. In addition, the NRC formed a working group consisting of several NRC offices in an effort to focus some resources on this issue. NRC also acknowledged that the NRC response to B&W's October 2, 2008 letter requesting details about licensing and waste issues was still under NRC review. Therefore, there could not be any discussion pertaining to those issues, as their resolution was predecisional.

B&W representatives presented an update on the Medical Isotope Production System (MIPS) project and design status, licensing approach, and project schedule. Key highlights include:

- B&W is working with the Department of Energy (DOE) and plans to enter into a cooperative agreement with DOE later this summer with a goal of being able to provide 50 percent of the domestic supply of Molybdenum-99 (Mo-99) by December, 2013.
- B&W proposed an accelerated licensing review and approval schedule with a construction permit application submitted in late 2010 and NRC approval in late 2011, and an operating license application submitted in late 2011 with NRC approval in early 2013.
- Although a site has not been selected all sites under consideration have already been environmentally characterized. B&W plans to submit an Environmental Report in early 2010 to expedite the licensing review process.
-

B&W & NRC Questions/Issues

- A member of the public questioned if the NRC had adequate resources to perform the necessary licensing review. NRC replied that this issue is a priority for NRC, but the NRC could not commit that all the necessary resources are in place.
- NRC staff questioned when the design would be finalized. B&W could not provide an answer but replied that a design contractor selection process was going to start soon and more details would be forthcoming.
- NRC staff indicated that they needed more design information, certainty of technical facts, and historical information in order to better assess the MIPS review. This information will be discussed at a follow-up meeting, perhaps in August, 2009.
- B&W indicated that they will proceed with the facility design and scheduling milestones, as discussed in their presentation, until they receive feedback from NRC on the open licensing and waste questions.

Comments and Questions

- An NRC staff member questioned B&W if the MIPS components would be made in America. B&W replied that the components would be made in America as much as possible, but some technology had gone outside the country and those components would have to be purchased accordingly.
- An individual stated that the NRC should consider including a representative from the Organization of Agreement States and or the Council of Radiation Control Program Directors in the NRC working group. NRC acknowledged the comment.
- An individual asked B&W why they needed a byproduct license to which they replied it would depend on the agreement state status of the location of the MIPS.
- An individual questioned the NRC as to when the B&W issues previously provided the NRC would be answered. The NRC replied that those issues were under staff review.
- An individual commented that the domestic production of Mo-99 could be done in a phased approach with the University of Missouri reactor being used as the near-term solution. Subsequently B&W MIPS would be reviewed as the long-term solution. This could focus NRC resources on the University of Missouri application in the short-term, and then to B&W in the longer-term.
- An individual asked B&W how many reactor modules would be constructed. B&W responded that they did not know that answer at this time.
- An individual asked if B&W planned to produce other useful medical isotopes. B&W replied that they would and the isotope type and quantity would be based on its commercial viability.

LIST OF MEETING ATTENDEES

JULY 8, 2009 CATEGORY 1 PUBLIC MEETING WITH

BABCOCK AND WILCOX COMPANY

NRC

Geoffrey Wertz
Kathryn Brock
Michael Zeitler
Kent Wood
Jenny Tobin
Sandra Wastler
Jenny Ojeda
Ram Tiwari
Glenda Villamar
Lisa London
Brittain Hill
Jenny Weil
Mary Adams
Patrick Castleman
Osvaldo Font
Tim Reed
Timothy McGinty
David Brown
Alexander Adams
Marcus Voth*
William Orders*
Undine Shoop*
David Decker*
Stephen Pierce*
James Dwyer*
Duane Hardesty*
Cindy Montgomery*

BABCOCK AND WILCOX (including contractors)

Evans Reynolds
Don Roy
Dan Glenn
Steve Schilthelm
Hugh Thompson
Sy Weiss
Ellen Kuo

PUBLIC

Richard Martin
Lynne Fairobent
Felix Killar
David Martin
Danielle Dean
Rick McGoey
Jim Lieberman
Parker Moore
Edwin Lyman
Robert Atcher*
Jack Wentz*
Noah Pope*
William Erwin*
Dale Simpson*
Lee Brunarski*
Lauren Killian*
Bruce Jolliff*
Fu-Min Su*
Michael Peters*

* Indicates participation via Webinar